Literature DB >> 19609729

Comparison of osteopontin, beta-catenin and hnRNP B1 expression in lung carcinomas.

Muhammet Emin Guldur1, Yasemin Kibar, Hale Deniz, Kemal Bakir.   

Abstract

This study was performed to compare osteopontin (OPN), beta-catenin and heterogeneous nuclear ribonucleoprotein B1 (hnRNP B1) immunreactivities in small cell lung carcinomas (SCLC) and non-small cell lung carcinomas (NSCLC). Correlation of these three antibodies with grade and clinicopathologic stage of the tumor in NSCLC was also investigated. Twenty-nine SCLC, 6 large cell carcinoma, 36 adenocarcinoma and 30 squamous cell carcinoma (SCC), totally 101 cases, were included in this study. OPN, beta-catenin and hnRNP B1 expressions were immunohistochemically evaluated. OPN positivity was 6.9% in SCLC and 67% in NSCLC. When NSCLC types were individually considered, OPN positivity was 66.7% in large cell carcinoma, 80% in SCC and 55.6% in adenocarcinomas. beta-catenin positivity was observed in 48.6% of NSCLC and none of SCLC cases. These results were statistically significant (p < 0.05). Neither grade nor stage of NSCLC was correlated with osteopontin, beta-catenin or hnRNP B1 immunreactivity. We observed that OPN and beta-catenin are useful in differentiating SCLC from NSCLC. This may be helpful in small lung biopsies where morphology is obscured by crush artifacts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609729     DOI: 10.1007/s12253-009-9187-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  13 in total

1.  Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer.

Authors:  R T Pirinen; P Hirvikoski; R T Johansson; S Hollmén; V M Kosma
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

2.  Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance.

Authors:  S Kase; K Sugio; K Yamazaki; T Okamoto; T Yano; K Sugimachi
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

3.  Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer.

Authors:  Veronika F E Zech; Margit Dlaska; Alexandar Tzankov; Wolfgang Hilbe
Journal:  Cancer Detect Prev       Date:  2006-10-25

4.  Differential osteopontin expression in lung cancer.

Authors:  J Zhang; K Takahashi; F Takahashi; K Shimizu; F Ohshita; Y Kameda; K Maeda; K Nishio; Y Fukuchi
Journal:  Cancer Lett       Date:  2001-10-10       Impact factor: 8.679

5.  Osteopontin expression and prognostic significance in non-small cell lung cancer.

Authors:  Valentina Donati; Laura Boldrini; Matteo Dell'Omodarme; Maria C Prati; Pinuccia Faviana; Tiziano Camacci; Marco Lucchi; Alfredo Mussi; Massimo Santoro; Fulvio Basolo; Gabriella Fontanini
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

6.  Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia.

Authors:  E Sueoka; N Sueoka; Y Goto; S Matsuyama; H Nishimura; M Sato; S Fujimura; H Chiba; H Fujiki
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer.

Authors:  Yong Soo Choi; Young Mog Shim; Sang-Hui Kim; Dae Soon Son; Hye-Sook Lee; Gou Young Kim; Joungho Han; Jhingook Kim
Journal:  Eur J Cardiothorac Surg       Date:  2003-09       Impact factor: 4.191

8.  hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung.

Authors:  Shulin Wu; Masami Sato; Chiaki Endo; Akira Sakurada; Boming Dong; Hirokazu Aikawa; Yan Chen; Yoshinori Okada; Yuhji Matsumura; Eisaburo Sueoka; Takashi Kondo
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

9.  Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer.

Authors:  Sylke Schneider; JiMin Yochim; Jan Brabender; Kazumi Uchida; Kathleen D Danenberg; Ralf Metzger; Paul M Schneider; Dennis Salonga; Arnulf H Hölscher; Peter V Danenberg
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

10.  Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4.

Authors:  J Zhou; J L Mulshine; E J Unsworth; F M Scott; I M Avis; M D Vos; A M Treston
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

View more
  6 in total

1.  Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Authors:  Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

Review 2.  Circulating tumor cell interactions with macrophages: implications for biology and treatment.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Transl Lung Cancer Res       Date:  2017-08

3.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.

Authors:  Gerhard Hamilton; Barbara Rath; Lukas Klameth; Maximilan J Hochmair
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

4.  Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis.

Authors:  Yang Liu; Xiaobin Gu; Qunying Lin; Tian Tian; Lijuan Shao; Chao Yuan; Bo Zhang; Kexing Fan
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer.

Authors:  Ane Kongsgaard Rud; Marius Lund-Iversen; Gisle Berge; Odd Terje Brustugun; Steinar K Solberg; Gunhild M Mælandsmo; Kjetil Boye
Journal:  BMC Cancer       Date:  2012-08-01       Impact factor: 4.430

6.  Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin.

Authors:  Anja Kafka; Davor Tomas; Vili Beroš; Hrvoje Ivan Pećina; Martina Zeljko; Nives Pećina-Šlaus
Journal:  Int J Mol Sci       Date:  2014-06-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.